Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity

Alnylam Pharmaceuticals (ALNY) closed 1.63% higher on August 7, 2025, with a trading volume of $0.50 billion, ranking 233rd in market activity. The stock’s performance was driven by robust second-quarter results, including a 17% year-over-year revenue increase to $773.7 million, and strong sales of its rare disease therapy Amvuttra, which exceeded expectations by a significant margin, per Oppenheimer. Analysts highlighted the drug’s potential for first-line market dominance, while the company announced a presentation at the Canaccord Genuity Growth Conference on August 12 to discuss strategic updates.

Recent analyst activity underscored optimism, with HC Wainwright reaffirming a “Moderate Buy” rating and Stifel Nicolaus reiterating a “Buy.” Earnings estimates for 2025 also rose, reflecting confidence in Amvuttra’s revenue contributions and the company’s RNAi therapeutics pipeline. Notably, Alnylam’s Amvuttra sales hit $150 million in its first full quarter, signaling strong adoption in treating hereditary angioedema. The stock’s rally aligns with broader healthcare sector gains, as the NYSE Health Care Index rose 1% during the same period.

The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the short-term efficacy of liquidity-focused strategies in volatile markets, particularly for high-volume stocks like ALNY, which benefited from concentrated investor interest and positive earnings momentum during the reporting period.